CD86 and myeloid sarcoma: Conventional DC of both healthy controls (Table 2(a)) and MS patients (Table 2(b)) acquire a mature phenotype following activation with proinflammatory stimuli, as evidenced by upregulation of the expression of CD80, CD86, CD83, and HLA-DR (Figure 3(a)).